| 07th week of 2009 patent applcation highlights part 37 |
| Patent application number | Title | Published |
|---|
| 20090041647 | Method for Producing Nanoparticulate Lanthanoide/Boron Compounds or Solid Substance Mixtures Containing Nanoparticulate Lanthanoide/Boron Compounds - The present invention relates to a process for preparing essentially isometric nanoparticulate lanthanide-boron compounds or solid mixtures comprising essentially isometric nanoparticulate lanthanide-boron compounds, which comprises
| 2009-02-12 |
| 20090041648 | Radiation detector crystal and method of formation thereof - A radiation detector crystal is made from Cd | 2009-02-12 |
| 20090041649 | PROCESS FOR THE MANUFACTURE OF HYDROGEN-RICH CYCLOSILOXANE - The present invention relates to a for controlled synthesis of hydrogen-rich cyclosiloxanes of the (H | 2009-02-12 |
| 20090041650 | Method for removing metal impurity from quartz component part used in heat processing apparatus of batch type - A method for removing a metal impurity from a quartz component part in a heat processing apparatus of a batch type includes placing a plurality of dummy substrates for allowing the metal impurity to be deposited thereon inside a process container with no product target substrates placed therein; then, supplying a chlorine-containing gas and water vapor into the process container and heating the quartz inner surface of the process container at a process temperature, thereby applying a baking process onto the quartz inner surface to discharge the metal impurity from the quartz inner surface and deposit the metal impurity onto the dummy substrates; and then, unloading the dummy substrates with the metal impurity deposited thereon from the reaction container. | 2009-02-12 |
| 20090041651 | Process for Jointly Obtaining a Chlorine Derivative and Crystals of Sodium Carbonate - An aqueous solution of sodium chloride is electrolysed in a cell ( | 2009-02-12 |
| 20090041652 | METHOD FOR SEPARATING CARBON NANOTUBES, METHOD FOR DISPERSING CARBON NANOTUBES AND COMPOSITIONS USED FOR THE METHODS - The separation of carbon nanotubes into metallic carbon nanotubes and semiconducting carbon nanotubes is made to be possible simultaneously with the dispersion of the carbon nanotubes by using viologen. | 2009-02-12 |
| 20090041653 | Method for the preparation of porous graphite carbon with high crystallinity using sucrose as a carbon precursor - The present invention relates to a process for preparing a porous graphite carbon with high crystallinity, which comprises the steps of: (a) hydrothermally treating sucrose (i.e. carbon precursor), transitional metal precursor and uniform-sized silica particles at the same time to prepare a polymer; and (b) carbonizing the polymer, which can provide a porous graphite carbon with remarkably improved crystallinity suitable for a catalyst support for a fuel cell. | 2009-02-12 |
| 20090041654 | Gas Recovery of Sulphur Hexafluoride - A system and method are provided for recovering a re-usable grade of sulphur hexafluoride (SF | 2009-02-12 |
| 20090041655 | Method for recovering iodine - An object of the present invention is to provide a method for recovering iodine, which can be carried out simply and economically without practicing mixing processing operation of iodine-containing material, an alkali metal compound and a solvent in advance before introducing to a combustion furnace. The object of the present invention can be attained by a method for recovering iodine which comprises feeding an iodine-containing solution containing iodine and/or iodine compound, a basic alkali metal compound solution and/or a basic alkaline earth metal compound solution separately to a roasting furnace, oxidatively decomposing a combustible material by heat treatment, and absorbing iodine and/or iodine salt contained in a component at heat treatment exit with water or an aqueous solution. | 2009-02-12 |
| 20090041656 | Nanoparticles of alumina and oxides of elements of main groups I and II of the periodic table, and their preparation - Nanoparticles are claimed which consist of 50-99.99% by weight of alumina and 0.01-50% by weight of metal oxide of elements of main group I and II of the Periodic Table. These nanoparticles are obtained by drying a suspension of aluminum chlorohydrate, oxide formers and, if desired, crystallization nuclei, followed by calcining and comminution of the resultant agglomerates. | 2009-02-12 |
| 20090041657 | Hydrogen generating material and method for producing the same, and method for producing hydrogen - A hydrogen generating material of the present invention includes at least one metal material selected from aluminum and aluminum alloy. The metal material has a surface film that includes a metal phase containing aluminum in the metallic state and an inactive phase containing an oxide or hydroxide of aluminum. A method for producing the hydrogen generating material of the present invention includes pulverizing aluminum or aluminum alloy in a liquid containing water and an organic solvent. A method for producing hydrogen of the present invention includes producing hydrogen by a reaction between the hydrogen generating material of the present invention and water. | 2009-02-12 |
| 20090041658 | Crystalline molecular sieve EMM-7, its synthesis and use - The crystalline molecular sieve material EMM-7 has, in its as-synthesized form, an X-ray diffraction pattern including d-spacing maxima substantially as set forth in Table 1: | 2009-02-12 |
| 20090041659 | Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse - The invention described herein provides for human antibodies produced in non-human animals that specifically bind to lipopolysaccharide (LPS) from strains Fisher Devlin (International Serogroups) It-2 (011), It-3 (02), It-4 (01), It-5 (010), It-6 (07), PA01 (05), 170003 (02), IATS016 (02/05), and 170006 (02). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein. | 2009-02-12 |
| 20090041660 | Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer (SCLC) - The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease and of patients having SCLC disease. The antibody-recognized SCLC-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing SCLC cells. | 2009-02-12 |
| 20090041661 | MEASUREMENT OF BIOSYNTHESIS AND BREAKDOWN RATES OF BIOLOGICAL MOLECULES THAT ARE INACCESSIBLE OR NOT EASILY ACCESSIBLE TO DIRECT SAMPLING, NON-INVASIVELY, BY LABEL INCORPORATION INTO METABOLIC DERIVATIVES AND CATABOLITIC PRODUCTS - Methods of determining rate of biosynthesis or breakdown of biological molecules from metabolic derivatives and catabolic products are disclosed herein. In particular, methods of measuring the rates of biosynthesis and breakdown of biological molecules inaccessible or not easily accessible to direct sampling by sampling metabolic derivatives and catabolic products in accessible biological samples are disclosed herein. | 2009-02-12 |
| 20090041662 | Method for Monitoring Patient or Subject Compliance with Medical Prescriptions, and Formulation for Use in the Method - The present invention provides a highly accurate method for monitoring patient or subject compliance with a medication prescription by collecting a sample of the exhaled air. The method of the present invention is easy and little burdens the patient or subject. | 2009-02-12 |
| 20090041663 | SIGMA-2 RECEPTOR RADIOTRACERS FOR IMAGING THE PROLIFERATIVE STATUS OF SOLID TUMORS - Novel benzamide compounds of Formula (I), Formula (II), and Formula (III), salts, water soluble salts, analogs and radiolabeled counterparts thereof as sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors. A method for diagnosing a mammal for the presence of a mammalian tumor therein comprises administering to the mammal a diagnostic imaging detectable effective amount of a benzamide compound having a structure illustrated in Formula (I), Formula (II) and Formula (III) and detecting binding of the compound to a tumor in the mammal. A method for diagnostic imaging of a mammalian tissue having cell surface sigma-2 receptors comprising administering to a mammal a diagnostic imaging amount of a compound having a structure illustrated in Formula (I) Formula (II) and Formula (III) and detecting an image of a tissue having an ample cells with sigma-2 receptors. | 2009-02-12 |
| 20090041664 | 5-Pyrrolidinylsulfonyl Isatin Derivatives - The present invention relates to novel 5-pyrrolidinylsulfonyl isatin derivatives, non-peptidyl Caspase binding Radioligands (CbRs) and CbR-transporter conjugates derived from said isatin derivatives, diagnostic compositions comprising said compounds of the invention and their use for non-invasive diagnostic imaging. | 2009-02-12 |
| 20090041665 | METHOD FOR GENE DELIVERY TO NEURONAL CELLS - The present invention relates to the use of axonal transport to deliver a baculovirus vector to a target neuronal cell by administering the vector to a site that is remote from the target cell. Such delivery allows for tracing of neuronal pathways and further a baculovirus vector may be used to deliver therapeutic gene to a target neuronal which may otherwise be not readily accessible, for the treatment of a neuronal disorder in a subject. | 2009-02-12 |
| 20090041666 | Ophthalmic formulations of Amyloid-beta contrast agent and methods of use thereof - The invention provides ophthalmic formulations of Amyloid-β contrast agents. Also provided are methods of using such formulations in the diagnosis of Alzheimer's Disease or a predisposition thereto as well as methods for the prognosis of Alzheimer's Disease. | 2009-02-12 |
| 20090041667 | Treatment of Depressive Disorders - The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds the treatment of depressive disorders. | 2009-02-12 |
| 20090041668 | Non-invasive localization of a light-emitting conjugate in a mammal - Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking the progression of disease or a pathogen within the animal, and for screening putative therapeutic compounds effective to inhibit the disease or pathogen. | 2009-02-12 |
| 20090041669 | Light-Emitting Biomarker - The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical or biological, in particular enzymatic, phenomenon, as well as a kit for implementing said method. | 2009-02-12 |
| 20090041670 | Near Infrared Fluorescent Contrast Agent And Method For Fluorescence Imaging - A near infrared fluorescent contrast agent which is excellent in permeability in a living tissue and enables specific imaging of tumor and/or blood vessel, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein R | 2009-02-12 |
| 20090041671 | PROTEIN CAGES FOR THE DELIVERY OF MEDICAL IMAGING AND THERAPEUTIC AGENTS - The present invention is directed to novel compositions and methods utilizing delivery agents comprising protein cages, medical imaging agents and therapeutic agents. | 2009-02-12 |
| 20090041672 | Drug for Treating or Diagnosing Vascular Lesion in the Skin or the Subcutaneous Soft Tissue Caused by Light Irradiation - A novel drug for treating a vascular lesion in the skin or the subcutaneous soft tissue caused by light irradiation which is efficacious in treating a vascular lesion in the deep part of the skin or the subcutaneous soft tissue caused by light irradiation without destroying normal cells on the skin surface and yet requires only a short shading time after the treatment. This drug for treating a vascular lesion in the skin or the subcutaneous soft tissue caused by light irradiation contains, as the active ingredient, mono-L-aspartyl chlorin e6, mono-L-glutamyl chlorin e6 or a pharmacologically acceptable salt thereof. | 2009-02-12 |
| 20090041673 | Thermally Crosslinked Contrast Agents - The present invention relates to a contrast agent comprising a plurality of nanoparticles, wherein each of the nanoparticles comprises: (a) a signal generating core; and (b) a polymeric shell coated on the signal generating core, wherein the polymeric shell comprises a water soluble hydoxysilyl- or alkoxysilyl-functionalized polymer and wherein the polymer shell is thermally crosslinked through hydroxysilyl or alkoxysilyl groups of the polymer. | 2009-02-12 |
| 20090041674 | TARGETED IRON OXIDE NANPARTICLES - Iron oxide nanoparticles comprising functional groups of the formula —X—NH | 2009-02-12 |
| 20090041675 | Organic compounds - A medicament comprising, separately or together, (A) a compound of formula I | 2009-02-12 |
| 20090041676 | Targeted Delivery of Lidocaine and Other Local Anesthetics and A Method For Treatment of Cough, Asthma and Tussive Attacks - An anti-tussive nebulized solution for targeted delivery of lidocaine into conducting and central airways. A method for treatment of cough and tussive attacks or episodes using said lidocaine solution. A nebulized lidocaine solution administered in daily dose from about 10 mg to 80 mg of lidocaine dissolved in a saline and nebulized into an aerosol having a mass median aerodynamic diameter 3 μm to 10 μm and a geometric standard deviation less than 1.7 using an electronic nebulizer. | 2009-02-12 |
| 20090041677 | AZEOTROPE-LIKE COMPOSITIONS OF 1-CHLORO-3,3,3-TRIFLUOROPROPENE AND METHYL IODIDE - An azeotropic or azeotrope-like composition comprising a mixture of methyl iodide, 1-chloro-3,3,3,-trifluoropropene, and optionally one or more of fluorocarbons and/or hydrofluorocarbons. The compositions are present as a gas, at temperatures of about 30° C. or below. The inventive compositions serve as a non-ozone-depleting gaseous fumigant which is useful in a variety of applications, in place of methyl bromide. These compositions serve as a drop-in replacement for gaseous methyl bromide, providing the benefits of a methyl iodide fumigant while also utilizing existing methyl bromide equipment. | 2009-02-12 |
| 20090041678 | Metronidazole-based dermatological foams and emulsions for the preparation thereof - Oil-in-water emulsions expandable into stable foams having diminished inhibitor of skin breathing and useful for the treatment of dermatological conditions/afflictions, e.g., rosacea, advantageously contain:
| 2009-02-12 |
| 20090041679 | HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO H5N1 INFLUENZA A VIRUS - A panel of IgG | 2009-02-12 |
| 20090041680 | Wax Foamable Vehicle and Pharmaceutical Compositions Thereof - Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided. | 2009-02-12 |
| 20090041681 | Anti-inflammatory inhalation pharmaceutical composition - The present invention is directed to the discovery of the anti-inflammatory properties of basic amino salts of acetylcysteine when administered directly to the lungs and/or the nose. | 2009-02-12 |
| 20090041683 | HAIR STYLING COMPOSITION - The present invention is related to a hair styling composition for keratin fibres especially for hair comprising at least one film forming polymer and at least one arylated silicone. | 2009-02-12 |
| 20090041684 | FORMULATION FOR PROPHYLAXIS OF ORAL CAVITY DISEASES - The invention relates to medicine, namely, to stomatology, in particular, to formulation for prophylaxis of oral cavity diseases. The formulation comprises: drinking water, glycerol, xylitol, silica, xanthan gum, methylparaben, propylparaben, titanium dioxide, perfume, bromelain, sodium saccharin, sodium lauryl sulfate or alkylamidobetain, calcium glycerophosphate, and magnesium chloride or glycerophosphate magnesium at following component ratio, % wt.: glycerol—20-25; xylitol—10-14; i 10 silica—22-26; xanthan gum—1.2-1.4; methylparaben—0.2-0.3; propylparaben—0.08-0.12; sodium saccharin—0.1-0.3; titanium dioxide—0.2-0.4; perfume—0.7-1.0; bromelain—0.1-0.7; sodium lauryl sulfate—1.2-1.4 or alkylamidobetain—1.2; calcium glycerophosphate—0.6-1.0; magnesium chloride—0.08-0.16 or magnesium glycerophosphate—0.16; and water—up to 100. | 2009-02-12 |
| 20090041685 | Cosmetic Delivery System and Process for Manufacture Thereof - A benefit agent delivery system for use in cosmetic or cleansing products is provided comprising a polysaccharide-zein complex, a benefit agent and a plasticiser. The delivery system enhances the stability of the benefit agent whilst providing for shear-triggered release of the benefit agent on application of a product to a substrate such as human skin. Also provided is a process for the preparation of the benefit agent delivery system. | 2009-02-12 |
| 20090041686 | Topical acne vulgaris composition with a sunscreen - Increased compliance in the use of topical sunscreens is obtained by combining a topical sunscreen agent in a formulation containing an antibacterial medication such as azelaic acid or an antibiotic. | 2009-02-12 |
| 20090041688 | Sunless tanning compositions comprising certain substituted polyamine compounds and methods of use - The present invention is directed to cosmetic and/or dermatological compositions for enhancing the rate of tanning human skin with sunless tanning compositions and providing the added benefit of simultaneously providing protection from ultraviolet light radiation. More particularly, the present invention is directed to a sunless tanning composition comprising a sunless tanning agent, a substituted polyamine compound and a cosmetically acceptable adjuvant. Methods of use of the instant compositions are disclosed as well. | 2009-02-12 |
| 20090041689 | POLYURETHANE DISPERSIONS BASED ON POLYCARBONATE POLYOLS AND SUITABLE FOR USE IN PERSONAL CARE PRODUCTS - The invention relates to a process for preparing an aqueous polyurethane dispersion suitable for use in personal care products, wherein the polyurethane is based on one or more polycarbonate polyols. | 2009-02-12 |
| 20090041690 | AUTOBRONZING COMPOSITION - The present invention pertains to an auto-bronzing composition including (i) at least one auto-bronzing agent, (ii) at least one auto-bronzing reactive material (“ARM”) chosen from the group consisting of amphiphilic copolymers of AMPS with at least one hydrophobic comonomer and (iii) at least one specific emulsifier. The emulsifier (iii) is preferably PEQ-100 stearate, glyceryl stearate, steareth-2 or steareth-21, or mixtures thereof. The emulsifier stabilises the ARM. It also pertains to the cosmetic use of this auto-bronzing composition for artificially tanning skin. | 2009-02-12 |
| 20090041691 | Sun protection compositions comprising semi-crystalline polymers and hollow latex particles - Topically applicable cosmetic/dermatological UV protection compositions having enhanced SPF contain at least one organic UV screening agent and/or at least one inorganic screening agent, such compositions also containing at least the following constituents (A) and (B):
| 2009-02-12 |
| 20090041692 | Methods of producing lignin peroxidase and its use in skin and hair lightening - Methods of producing lignin peroxidase are provided. Also provided are methods and cosmetic compositions suitable for skin and hair lightening as well as kits and an article-of manufacturing including active ingredients for skin and hair lightening. | 2009-02-12 |
| 20090041693 | BLEACHING/HIGHLINGTING COMPOSITION - The present invention relates to water free bleaching composition in form of a dust free powder or a suspension, which comprises at least one arylated silicone at a concentration of 1 to 50% by weight calculated to total composition. | 2009-02-12 |
| 20090041694 | Preparation, in particular cosmetic preparation, production and use thereof - A preparation comprising at least one silicone, at least one PEG/PPG dimethicone with 15 to 20 units of PEG and PPG respectively as an emulsifier, a lipid phase, water in a proportion of 0.1 to 5% with respect to the total weight of the composition and at least one particulate ingredient. | 2009-02-12 |
| 20090041695 | Compositions for making up keratinous materials - The present invention relates to a cosmetic composition comprising:
| 2009-02-12 |
| 20090041696 | Compositions for Making Up Keratinous Materials - The present invention relates to a cosmetic composition comprising:
| 2009-02-12 |
| 20090041697 | Film-Forming Compositions for Protecting Skin From Body Fluids and Articles Made Therefrom - A film-forming barrier composition useful for protecting the skin from body fluids, such as urine, feces, menses. The composition includes a skin conditioning agent, a viscosity enhancing agent and an oleophilic film-forming agent. Optionally, the lotion may include a skin care ingredients for treating or maintaining skin health. The composition may be applied to the skin by suitable delivery vehicles, such as absorbent articles or components thereof, sheet materials, pads, bandages, sponges, foam pads, pumps, sprays, depending on the viscosity of the composition. | 2009-02-12 |
| 20090041698 | Cosmetic product in the form of compact powder comprising a message informing the user - A compressed powder product ( | 2009-02-12 |
| 20090041699 | TWO-PHASE COMPOSITION FOR CONDITIONING HAIR - Present invention is related to a composition for conditioning hair comprising two optically separated phases when standing at zero shear rate which becomes homogeneous upon shaking. The object of the present invention is a composition for hair comprising 5 to 50%, by weight oil phase, calculated to total composition, and 50 to 95%, by weight, aqueous phase, calculated to total composition, wherein oil phase comprises at least one arylated silicone. | 2009-02-12 |
| 20090041700 | COMPOSITION FOR PERMANENT SHAPING HUMAN HAIR | 2009-02-12 |
| 20090041701 | Hair care composition - A method for relaxing hair comprising the following steps:
| 2009-02-12 |
| 20090041702 | Conditioning Composition for Hair - The present invention is related to a conditioning composition for hair based on polyphenols, Ubichinone and UV filters. The conditioning composition of the present invention can be in the form of a shampoo, cleansing-conditioning composition, or in the form of a conditioner used after washing hair with cleansing compositions. It has surprisingly been found out that a composition comprising at least one polyphenol, at least one UV filter and at least one ubichinone protects hair from environmental influences and hair treated with such a composition looks attractive and has its natural excellent shine, volume and body, elasticity and it is easily manageable. | 2009-02-12 |
| 20090041703 | TWO OR MULTI-PHASE COMPOSITION FOR CONDITIONING HAIR - Present invention is related to a composition for conditioning hair comprising two or more optically separated phases when standing at zero shear rate which becomes homogeneous upon shaking. The object of the present invention is a composition for hair comprising 5 to 50%, by weight oil phase, calculated to total composition, and 50 to 95%, by weight, aqueous phase, calculated to total composition, wherein oil phase comprises at least one compound selected from compounds according to general formula | 2009-02-12 |
| 20090041704 | MULTI-PHASE COMPOSITION FOR CONDITIONING HAIR - The inventors of the present invention have surprisingly found out that mixing an additional component prior to application which is preferably an emulsion to already existing two or more phase composition comprising an oil phase and a water phase wherein two or more phases are optically separated at zero shear rate and becomes homogeneous upon shaking and returns again to optically separated two or more phases upon release of agitation and mixes to a homogeneous composition when all phases are mixed improves hair shine, elasticity, manageability and combability and adds volume and body when especially a compound described below is included into the composition. It should be noted that after mixing all phase the composition is used immediately or in a short period of time so that the formed composition by mixing all phases does not have to have long term stability. It is enough when it is homogeneous during application onto hair. | 2009-02-12 |
| 20090041705 | COMPOSITION FOR KERATIN FIBRES - The present invention relates to a conditioning and shine enhancing composition for keratin fibres especially human hair. Accordingly the subject of the present invention is an aqueous composition comprising at least one mono alkyl quaternary ammonium surfactant at a concentration of 0.01 to 10% by weight, and at least one arylated silicone at a concentration of 0.001 to 5% by weight, calculated to total composition. | 2009-02-12 |
| 20090041706 | CONDITIONING COMPOSITION FOR HAIR - The present invention is related to a conditioning composition for hair comprising at least one polyphenol and at least one silicone quaternary compound. The conditioning composition of the present invention can be in the form of a shampoo, cleansing—conditioning composition, or in the form of a conditioner used after washing hair with cleansing compositions. It has surprisingly been found out that a composition comprising at least one polyphenol and at least one silicone quaternary compound protects hair from environmental influences and hair treated with such a composition looks attractive and has its natural excellent shine, volume and body, elasticity and it is easily manageable. Accordingly the first object of the present invention is a conditioning composition for hair comprising at least one polyphenol and at least one silicone quaternary compound. | 2009-02-12 |
| 20090041707 | CONDITIONING COMPOSITION FOR HAIR - The present invention is related to a conditioning composition for hair comprising at least one arylated silicone and at least one silicone quaternary compound. The conditioning composition of the present invention can be in the form of a shampoo, cleansing-conditioning composition, or in the form of a conditioner used after washing hair with cleansing compositions. It has surprisingly been found out that a composition comprising at least one arylated silicone and at least one silicone quaternary compound gives hair its natural excellent shine, volume and body, elasticity and it is easily manageable. | 2009-02-12 |
| 20090041708 | Conditioning Composition for Hair Comprising Optical Brightener - The present invention is related to a conditioning composition for hair comprising optical brightener and ubichinone. The conditioning composition of the present invention can be in the form of a shampoo, cleansing—conditioning composition, or in the form of a conditioner used after washing hair with cleansing compositions. | 2009-02-12 |
| 20090041709 | Conditioning Composition for Keratin Fibres - The present invention relates to a conditioning composition for keratin fibres especially human hair comprising particular cationic polymers and a cationic silicone compound. The present inventor has surprisingly found out that an aqueous hair conditioning composition comprising at least two cationic polymers, one being a cationic polymer with multiple cationic sites and with multiple ester groups in its molecule and the other cationic polymer is being a cellulose derivative, and a cationic or cationizable silicone improves hair combability, smoothness shine, elasticity and more interestingly hair treated with such a composition has volume and body and excellently manageable. | 2009-02-12 |
| 20090041710 | CONDITIONING COMPOSITION FOR HAIR - The present invention is related to a conditioning composition for hair comprising at least one polyphenol and at least one arylated silicone selected from phenyl methicone, phenyl trimethicone, diphenyl dimethicone, diphenylsiloxy phenyl trimethicone, tetramethyl tetraphenyl trisiloxane, triphenyl trimethicone, teramethly tetraphenyl trisiloxane and pentaphenyl trimethly trisiloxane. The conditioning composition of the present invention can be in the form of a shampoo, cleansing-conditioning composition, or in the form of a conditioner used after washing hair with cleansing compositions. It has surprisingly been found out that a composition comprising at least one polyphenol, at least one arylated silicone protects hair from environmental influences and hair treated with such a composition looks attractive and has its natural excellent shine, volume and body, elasticity and it is easily manageable. Accordingly the first object of the present invention is a conditioning composition for hair comprising at least one polyphenol and at least one arylated silicone. | 2009-02-12 |
| 20090041711 | CONDITIONING COMPOSITION FOR KERATIN FIBRES - The present invention relates to a conditioning composition for keratin fibres especially human hair comprising particular cationic cellulose polymer and a cationic or cationizable silicone compound. | 2009-02-12 |
| 20090041712 | WATER-IN-SILICONE EMULSION COMPOSITIONS - The present invention relates to a composition containing a retinoid and/or peptide complexed with a copper ion wherein the composition is a water-in-silicone emulsion, and the use thereof. | 2009-02-12 |
| 20090041713 | Hair Care Composition - A method for relaxing hair comprising the following steps:
| 2009-02-12 |
| 20090041714 | Polymer-factor VIII moiety conjugates - Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient. | 2009-02-12 |
| 20090041715 | Epothilone Combinations - The invention relates to combinations of (a) an epothilone with (b) two or more other antineoplastic agents for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease. | 2009-02-12 |
| 20090041716 | CRYSTALLINE FORM OF METHYL ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1((2S)-2-((METHOXYCARBONYL)AMINO)-3-METH- YLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-- YL)-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SALT - The present disclosure generally relates to a crystalline form of methyl ((1S)-1-(((2S)-2-(5-(4′-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1 H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt. The present disclosure also generally relates to a pharmaceutical composition comprising a crystalline form, as well of methods of using a crystalline form in the treatment of Hepatitis C and methods for obtaining such crystalline form. | 2009-02-12 |
| 20090041717 | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN NERVE GROWTH FACTOR - A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with K | 2009-02-12 |
| 20090041718 | Methods of Modulating Cytokine Activity; Related Reagents - Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor. | 2009-02-12 |
| 20090041719 | Method for screening therapeutic agent for glomerular disorder - The present invention relates to a method for screening a compound for preventing, ameliorating or treating glomerular lesions or disease of kidney, characterized by assaying the regulating activity of compound on 4F2hc expression shown by contacting human peripheral blood mononuclear cells or monocytes or an established line of human cultured cells having a nature of human macrophages with macrophage-activating substances. The screening method is useful for screening compounds capable of preventing, ameliorating or treating glomerular lesions or disease of kidney. | 2009-02-12 |
| 20090041720 | HETEROARYL SUBSTITUTED THIAZOLES - The invention provides heteroaryl substituted thiazolo compounds of Formula I and II | 2009-02-12 |
| 20090041721 | ARYLALKOXYL HEPATITIS C VIRUS PROTEASE INHIBITORS - The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2009-02-12 |
| 20090041722 | INDOLE INDANE AMIDE COMPOUNDS USEFUL AS CB2 AGONISTS AND METHOD - Indole indane amides which are CB2 agonists are provided which have the structure | 2009-02-12 |
| 20090041723 | Compounds and methods for treatment of HCV - Aryl substituted pyrazole derivatives are provided, as well as processes for their preparation. The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention, alone or in combination with additional antiviral agents, in a therapeutically effective amount. | 2009-02-12 |
| 20090041724 | Protein Delivery System - The present invention relates to a virus-like particle (VLP) having a plasma membrane-derived lipid bilayer envelope, said VLP further comprising a viral structural protein, or fragment or derivative thereof, capable of forming an enveloped VLP, a fusiogenic protein and a recombinant target protein; methods for the delivery of recombinant target proteins to cells using said VLP, therapeutic methods using said VLP, compositions and kits comprising said VLP, methods of producing said VLP, and vectors and host cells for producing said VLP are also described. | 2009-02-12 |
| 20090041725 | Replication-Deficient RNA Viruses as Vaccines - The present invention relates to a genome-replication-deficient and transcription-competent negative-strand RNA virus, which can be used for the expression of transgenes and in particular for the area of vaccine development. | 2009-02-12 |
| 20090041726 | TUMOR THERAPY WITH HIGH AFFINITY LAMININ RECEPTOR-TARGET VECTORS AND COMBINATIONS WITH CHEMOTHERAPEUTIC AGENTS - The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis. | 2009-02-12 |
| 20090041727 | Compositions and Methods for Microbe Storage and Delivery - The present invention relates to the field of bacteriology. In particular, the invention relates to compositions of probiotic microbes and methods for making and using such compositions, e.g. in the treatment and prevention of catheter associated urinary tract infections. | 2009-02-12 |
| 20090041728 | Proteoglycan Degrading Mutants for the Treatment of CNS - The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease. | 2009-02-12 |
| 20090041729 | Process for Decellularizing Soft-Tissue Engineered Medical Implants, and Decellularized Soft-Tissue Medical Implants Produced - The invention provides methodologies and apparatus for producing acellular soft-tissue implants, both in small quantities and in commercializable quantities. Such soft-tissue implants include vascular graft substitutes. An acellular graft is produced by subjecting the tissue sample to an induced pressure mediated flow of an extracting solution, followed by inducing a pressure mediated flow of a treating solution, then washing the treated tissue to produce the acellular graft. The acellular grafts produced are uniform and non-immunogenic. The inventive method allows for the production of multiple decellularized soft tissue implants, where processing time is significantly less than prior art processes and the number of implants produced per day is increased over prior art processes. In clinical use, the decellularized grafts produced exhibit significantly improved in long-term durability and function. | 2009-02-12 |
| 20090041730 | Joint Repair Using Mesenchymal Stem Cells - A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue. | 2009-02-12 |
| 20090041731 | Treatment for Diabetes - Methods and compositions for treating diabetes mellitus in a patient in need thereof are provided. The methods include administering to a patient a composition providing a gastrin/CCK receptor ligand, e.g., a gastrin, and/or an epidermal growth factor (EGF) receptor ligand, e.g., TGF-α, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g., a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g., a TGF-α gene. The methods also include transplanting into a patient cultured pancreatic islets in which mature insulin-secreting beta cells are proliferated by exposure to a gastrin/CCK receptor ligand and an EGF receptor ligand. | 2009-02-12 |
| 20090041732 | Survivin Peptides As Cancer Vaccines - Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual. | 2009-02-12 |
| 20090041733 | METHODS FOR CELL MOBILIZATION USING IN VIVO TREATMENT WITH HYALURONAN (HA) - The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or G-CSF. | 2009-02-12 |
| 20090041734 | USE OF CELL IMPLANTS IN BLADDER AND GUT OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF PEPTIDES - Provided are means and method for the production of proteins in non-production in non-human animals. Cells producing a protein of interest is implanted in said non-human animal whereupon produced protein is harvested. In a preferred embodiment cells are implanted into a bladder or gut of said non-human animal | 2009-02-12 |
| 20090041735 | CD34 Stem cell-related methods and compositions - This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 | 2009-02-12 |
| 20090041736 | SYNBIOTIC MIXTURE - This invention relates to a preparation comprising a probiotic bacterial strain and a prebiotic mixture comprising 5-70 wt % of at least one N-acetylated oligosaccharide selected from the group comprising Ga1NAcα1,3Ga1β1,4G1c and Ga1β1,6Ga1NAcα1,3Ga1β1,4G1c, 20-95 wt % of at least one neutral oligosaccharide selected from the group comprising Ga1β1,6Ga1, Ga1β1,6Ga1β1,4G1c Ga1β1,6Ga1β1,6G1c, Ga1β1,3Ga1β1,3G1c, Ga1β1,3Ga1β1,4G1c, Ga1β 1,6Ga1β 1,6Ga1β 1,4G1c, Ga1β 1,6Ga1β 1,3Ga1β 1,4GIc Ga1β 1,3Ga1β 1,6Ga1β 1,4GIc and Ga1β1,3Ga1β1,3Ga1β1,4G1c and 2-50 wt % of at least one sialylated oligosaccharide selected from the group comprising NeuAcα2,3Ga1β1,4G1c and NeuAcα2,6Ga1β1,4G1c. The invention extends to food products comprising said preparation and to the use of the preparation in the prevention and treatment of infections. | 2009-02-12 |
| 20090041737 | COLD STORAGE OF MODIFIED PLATELETS - A method for storing and using platelets and an associated platelet structure. At least one modified platelet is formed. Each modified platelet includes a platelet and at least one polymerated chemical. Each polymerated chemical includes a polymer covalently bonded directly to the platelet or includes the polymer and a linker molecule such that the linker molecule is covalently bonded to the platelet and the polymer is covalently attached to the linker molecule. The polymer of each polymerated chemical of each modified platelet is polyethylene glycol (PEG) or a PEG derivative. Forming each modified platelet does not include modifying the platelet membrane of each platelet with a glycan-modifying agent. The at least one modified platelet is stored in a temperature range below 0° C. After being stored, the at least one modified platelet may be introduced into a subject to treat a condition related to a reduced platelet function. | 2009-02-12 |
| 20090041738 | Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells - The present invention provides novel methods for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator, wherein the inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-β, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors. | 2009-02-12 |
| 20090041739 | Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells - The present invention provides novel methods for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator, wherein the inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-β, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors. | 2009-02-12 |
| 20090041740 | CANCER TREATMENT BY METABOLIC MODULATIONS - The invention provides compositions and methods for inhibiting the growth or proliferation of hyperproliferative cells or inducing regression of hyperproliferative cells. More specifically, the invention provides compositions and methods for stimulating glycogen accumulation in target cells (e.g., hyperproliferative cells) in order to increase glycogen to a level that is toxic to the target cell. | 2009-02-12 |
| 20090041741 | MODIFIED ENZYME AND TREATMENT METHOD - There is disclosed an isolated, modified recombinant β-glucuronidase wherein the modification is having its carbohydrate moeties chemically modified so as to reduce its activity with respect to mannose and mannose 6-phosphate cellular delivery system while retaining enzymatic activity Also disclosed are methods for the treatment of lysosomal storage disease in mammals wherein the mammal is administered a therapeutically effective amount of isolated, modified recombinant β-glucuronidase whereby said storage diseased is relieved in the brain and visceral organs of the mammal. Also disclosed are other lysosomal enzymes within the scope of the invention. | 2009-02-12 |
| 20090041742 | HUMAN DNASE II - This invention relates to a novel human deoxyribonuclease, referred to as human DNase II. The invention provides nucleic acid sequences encoding human DNase II, thereby enabling the production of human DNase II by recombinant DNA methods in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and diagnostic and therapeutic uses of human DNase II. | 2009-02-12 |
| 20090041744 | Dimeric and Multimeric FVIIa Compounds - The present invention relates to dimeric or multimeric FVIIa compounds comprising at least two FVIIa polypeptides covalently connected such as to retain the intrinsic catalytic activity of the FVIIa polypeptides. | 2009-02-12 |
| 20090041745 | MODULATORS OF PARAPTOSIS AND RELATED METHODS - The invention is directed to a method of modulating paraptotic cell death in a cell by contacting the cell with an effective amount of a compound selected from the group consisting of ceramide, Tumor Necrosis Factor (TNF), caspase-7, caspase-8, α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA), kainic acid and glutamic acid, wherein the effective amount of the compound induces paraptotic death of the cell. The invention further is directed to a method of inhibiting paraptotic cell death in a cell by contacting the cell with an effective amount of a compound selected from the group consisting of Alg-2-interacting protein 1 (AIP-1), Jun N-terminal kinase 1 (JNK1) neutralizing agent, Jun N-terminal kinase 2 (JNK2) neutralizing agent, TNF Receptor-Associated Factor 2 (TRAF2) neutralizing agent, ortho-phenanthroline and the JNK inhibitor SP 600125, wherein the effective amount of the compound inhibits paraptotic death of the cell. | 2009-02-12 |
| 20090041746 | Combination therapy with IgA1 proteases - The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed. | 2009-02-12 |
| 20090041747 | Compounds for Stabilizing Factor VII Polypeptide Formulations - The invention relates to novel compounds with formula (I) and their use in stabilization of Factor VIIa or other Factor VII polypeptides, particularly in aqueous liquid compositions thereof. | 2009-02-12 |
| 20090041748 | Fibrinogen-Based Tissue Adhesive Containing an Elastase Inhibitor - The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor. | 2009-02-12 |
| 20090041749 | Compositions and methods for the diagnosis and treatment of tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 2009-02-12 |
